Steven Leonard Chapman Sells 85,299 Shares of Natera (NASDAQ:NTRA) Stock

Natera, Inc. (NASDAQ:NTRA) CEO Steven Leonard Chapman sold 85,299 shares of the company’s stock in a transaction dated Monday, February 2nd. The stock was sold at an average price of $230.72, for a total value of $19,680,185.28. Following the completion of the transaction, the chief executive officer directly owned 127,881 shares of the company’s stock, valued at approximately $29,504,704.32. This trade represents a 40.01% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Steven Leonard Chapman also recently made the following trade(s):

• On Tuesday, February 3rd, Steven Leonard Chapman sold 4,725 shares of Natera stock. The stock was sold at an average price of $230.77, for a total value of $1,090,388.25.
• On Wednesday, January 28th, Steven Leonard Chapman sold 3,648 shares of Natera stock. The shares were sold at an average price of $237.66, for a total transaction of $866,983.68.
• On Tuesday, January 27th, Steven Leonard Chapman sold 2,322 shares of Natera stock. The shares were sold at an average price of $240.53, for a total transaction of $558,510.66.
• On Wednesday, January 21st, Steven Leonard Chapman sold 1,590 shares of Natera stock. The stock was sold at an average price of $235.00, for a total transaction of $373,650.00.
• On Tuesday, January 20th, Steven Leonard Chapman sold 71,932 shares of Natera stock. The shares were sold at an average price of $234.74, for a total transaction of $16,885,317.68.
• On Friday, January 2nd, Steven Leonard Chapman sold 3,848 shares of Natera stock. The shares were sold at an average price of $229.08, for a total transaction of $881,499.84.
• On Monday, December 1st, Steven Leonard Chapman sold 4,400 shares of Natera stock. The shares were sold at an average price of $238.07, for a total transaction of $1,047,508.00.

Natera Stock Down 4.1%

Shares of Natera stock opened at $197.08 on Friday. Natera, Inc. has a twelve month low of $125.38 and a twelve month high of $256.36. The business has a 50-day moving average price of $234.15 and a 200-day moving average price of $195.75. The firm has a market cap of $27.26 billion, a price-to-earnings ratio of -86.06 and a beta of 1.64.

Natera (NASDAQ:NTRA) last released its quarterly earnings results on Friday, November 7th. The medical research company reported ($0.64) earnings per share for the quarter, missing the consensus estimate of ($0.39) by ($0.25). The firm had revenue of $592.18 million for the quarter, compared to analysts’ expectations of $514.55 million. Natera had a negative net margin of 14.61% and a negative return on equity of 25.07%. The business’s quarterly revenue was up 34.7% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.26) EPS. On average, equities analysts expect that Natera, Inc. will post -1.49 EPS for the current fiscal year.

Natera News Roundup

Here are the key news stories impacting Natera this week:

• Positive Sentiment: Regulatory/catalyst: Natera submitted a PMA to the FDA for Signatera CDx to detect minimal residual disease in bladder cancer after positive phase‑3 results — a potential pathway to a companion‑diagnostic revenue stream and better reimbursement/clinical adoption if approved. Natera files Signatera CDx PMA (Zacks)
• Neutral Sentiment: Routine insider trims: Several non‑executive insiders (e.g., Solomon Moshkevich, John Fesko) sold modest, single‑digit percentages of their positions; these look like routine liquidity actions but add incremental supply. InsiderTrades report on recent sales
• Negative Sentiment: Material CEO sale: CEO Steven Chapman sold 85,299 shares (~40% reduction) on Feb 2 for roughly $19.7M — a large, high‑visibility block that investors commonly view as a negative signal and that likely amplified downward pressure. CEO Form 4 (SEC)
• Negative Sentiment: Additional executive selling: CEO Chapman sold another 4,725 shares (Feb 3) and CFO Michael Burkes Brophy sold 6,939 shares (Feb 3), further trimming insider ownership and reinforcing near‑term selling pressure. CEO additional Form 4 CFO Form 4 (SEC)

Wall Street Analyst Weigh In

NTRA has been the topic of several recent research reports. TD Cowen restated a “buy” rating on shares of Natera in a research report on Wednesday, January 7th. BNP Paribas Exane raised Natera to a “hold” rating and set a $172.00 price objective on the stock in a research note on Monday, October 27th. Guggenheim raised their price objective on Natera from $230.00 to $270.00 and gave the company a “buy” rating in a research note on Monday, January 5th. JPMorgan Chase & Co. lifted their target price on Natera from $250.00 to $260.00 and gave the stock an “overweight” rating in a report on Monday, December 15th. Finally, Stephens increased their price target on Natera from $197.00 to $235.00 and gave the company an “overweight” rating in a report on Thursday, November 13th. One analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $249.20.

Hedge Funds Weigh In On Natera

A number of large investors have recently bought and sold shares of the business. Vanguard Group Inc. increased its stake in Natera by 2.3% in the second quarter. Vanguard Group Inc. now owns 12,676,653 shares of the medical research company’s stock worth $2,141,594,000 after purchasing an additional 282,826 shares during the period. JPMorgan Chase & Co. increased its stake in Natera by 9.4% in the 3rd quarter. JPMorgan Chase & Co. now owns 11,628,914 shares of the medical research company’s stock worth $1,871,914,000 after buying an additional 1,003,129 shares during the period. State Street Corp lifted its holdings in Natera by 2.2% during the 3rd quarter. State Street Corp now owns 3,389,599 shares of the medical research company’s stock valued at $545,624,000 after buying an additional 72,087 shares in the last quarter. Franklin Resources Inc. boosted its position in Natera by 37.5% in the 3rd quarter. Franklin Resources Inc. now owns 2,665,013 shares of the medical research company’s stock valued at $428,987,000 after buying an additional 727,366 shares during the period. Finally, Geode Capital Management LLC boosted its position in Natera by 7.0% in the 2nd quarter. Geode Capital Management LLC now owns 2,552,725 shares of the medical research company’s stock valued at $430,640,000 after buying an additional 166,768 shares during the period. Hedge funds and other institutional investors own 99.90% of the company’s stock.

Natera Company Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.